IL1B and Alzheimer disease: The NLRP3 inflammasome activation results in the secretion of caspase-1-mediated IL-1β and IL-18 by microglial cells, and is associated with the development and exacerbation of AD [10]; accordingly, the modulation of this microglia activation is considered a critical therapeutic strategy to attenuate neuroinflammation [6,7].